Diagnostic potential for a serum miRNA neural network for detection of ovarian cancer

Elias, Kevin M.; Fendler, Wojciech; Stawiski, Konrad; Fiascone, Stephen; Vitonis, Allison F.; Berkowitz, Ross S.; Frendl, György; Konstantinopoulos, Panagiotis A.; Crum, Christopher P.; Kędzierska, Magdalena; Cramer, Daniel W.; Chowdhury, Dipanjan

doi:10.7554/elife.28932

Cited by 111 publications

(106 citation statements)

References 58 publications

Supporting

Mentioning

104

Contrasting

Order By: Relevance

“…To the best of our knowledge, this is the most comprehensive miRNA profiling for breast cancer that has been conducted thus far, with a total of 180 malignant and benign breast lesions screened for the expression of 2,083 miRNA transcripts. To date, only a few cancer studies have deployed NGS as a tool in circulating miRNA biomarker discovery [47,48], with none reported for breast cancer. NGS was chosen as the profiling platform in this study due to its high-throughput capabilities and superior detection sensitivity as compared to other methods such as microarray and real-time qRT-PCR.…”

Section: Discussionmentioning

confidence: 99%

A Circulating miRNA Signature for Stratification of Breast Lesions among Women with Abnormal Screening Mammograms

Loke

Munusamy

Koh

et al. 2019

Cancers

View full text Add to dashboard Cite

Although mammography is the gold standard for breast cancer screening, the high rates of false-positive mammograms remain a concern. Thus, there is an unmet clinical need for a non-invasive and reliable test to differentiate between malignant and benign breast lesions in order to avoid subjecting patients with abnormal mammograms to unnecessary follow-up diagnostic procedures. Serum samples from 116 malignant breast lesions and 64 benign breast lesions were comprehensively profiled for 2,083 microRNAs (miRNAs) using next-generation sequencing. Of the 180 samples profiled, three outliers were removed based on the principal component analysis (PCA), and the remaining samples were divided into training (n = 125) and test (n = 52) sets at a 70:30 ratio for further analysis. In the training set, significantly differentially expressed miRNAs (adjusted p < 0.01) were identified after correcting for multiple testing using a false discovery rate. Subsequently, a predictive classification model using an eight-miRNA signature and a Bayesian logistic regression algorithm was developed. Based on the receiver operating characteristic (ROC) curve analysis in the test set, the model could achieve an area under the curve (AUC) of 0.9542. Together, this study demonstrates the potential use of circulating miRNAs as an adjunct test to stratify breast lesions in patients with abnormal screening mammograms.

show abstract

Section: Discussionmentioning

confidence: 99%

A Circulating miRNA Signature for Stratification of Breast Lesions among Women with Abnormal Screening Mammograms

Loke

Munusamy

Koh

et al. 2019

Cancers

View full text Add to dashboard Cite

show abstract

“…However, the presence of several variables, such as the detection in plasma or serum, centrifugation parameters, anticoagulants used for blood collection, methods for RNA extraction and amplification, as well as different methods of patients'stratification, determine a variability in the detection of miR expression levels. Indeed, a robust validation of methodology to detect them needs to be standardized before introducing it as a routine laboratory test [73] to guide clinical decision making., Moreover, standardized systems of big data analysis and management should be set up for data interpretation [178], the development of neural network based software could help the interpretation of the miRNA signature of specific patients [179].…”

Section: Discussionmentioning

confidence: 99%

The circulating miRNAs as diagnostic and prognostic markers

Terrinoni

Calabrese

Basso

et al. 2018

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

A large portion of the human genome transcribes RNA sequences that do not code for any proteins. The first of these sequences was identified in 1993, and the best known noncoding RNAs are microRNA (miRNAs). It is now fully established that miRNAs regulate approximately 30% of the known genes that codify proteins. miR-NAs are involved in several biological processes, like cell proliferation, differentiation, apoptosis and metastatization. These RNA products regulate gene expression at the post-transcriptional level, modulating or inhibiting protein expression by interacting with specific sequences of mRNAs. Mature miRNAs can be detected in blood plasma, serum and also in a wide variety of biological fluids. They can be found associated with proteins, lipids as well as enclosed in exosome vesicles. We know that circulating miRNAs (C-miRNAs) can regulate several key cellular processes in tissues different from the production site. C-miRNAs behave as endogenous mediators of RNA translation, and an extraordinary knowledge on their function has been obtained in the last years. They can be secreted in different tissue cells and associated with specific pathological conditions. Significant evidence indicates that the initiation and progression of several pathologies are "highlighted" by the presence of specific C-miRNAs, underlining their potential diagnostic relevance as clinical biomarkers. Here we review the current literature on the possible use of this new class of molecules as clinical biomarkers of diseases.

show abstract

“…Like in classical flow cytometry, the biotin is labeled with a streptavidin reporter complex that will be read in a cytometer. The fluorescent intensities of each coded particle will indicate the miRNA expression level (Elias et al, 2017;Leng et al, 2018). Multiplexed microarray profiling was used to identify let-7b and miR-199a as the most significant discriminators associated with metastasis in uveal melanoma, and the results were validated by qPCR (Worley et al, 2008).…”

Section: Mirna Multiplexing Systemsmentioning

confidence: 99%

miRNAs in the Diagnosis and Prognosis of Skin Cancer

Neagu

Constantin

Creţoiu

et al. 2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Skin cancer is, at present, the most common type of malignancy in the Caucasian population. Its incidence has increased rapidly in the last decade for both melanoma and non-melanoma skin cancer. Differential expression profiles of microRNAs (miRNAs) have been reported for a variety of different cancers, including skin cancers. Since miRNAs' discovery as regulators of gene expression, their importance grew in the field of oncology. miRNAs can post-transcriptionally regulate gene expression, tumor initiation, development progression, and aggressiveness. Nowadays, these short regulatory RNAs are perceived as one of the epigenetic markers for the identification of new diagnostic and/or prognostic molecular markers. Moreover, as miRNAs can drive tumorigenesis, they might eventually represent new therapy targets. Some miRNAs are pleiotropic, such as miR-214, which was found deregulated in several other tumors besides skin cancers. Some others are specific for one or more skin cancer types, like miR-21 and miR-221 for cutaneous melanoma and cutaneous squamous carcinoma or miR-155 for melanoma and cutaneous lymphoma. The goal of this review was to summarize some of the main miRNA detection technologies that are used to evaluate miRNAs in tissues and body fluids. Furthermore, their quantification limits, conformity, and robustness are discussed. Aberrant miRNA expression is analyzed for cutaneous melanoma, cutaneous squamous cell carcinoma (CSCC), skin lymphomas, cutaneous lymphoma, and Merkel cell carcinoma (MCC). In this type of disease, miRNAs are described as potential biomarkers to diagnose early lesion and/or early metastatic disease. In the future, whether in tissue or circulating in body fluids, miRNAs will gain their place in skin cancer diagnosis, prognosis, and future therapeutic targets.

show abstract

Diagnostic potential for a serum miRNA neural network for detection of ovarian cancer

Cited by 111 publications

References 58 publications

A Circulating miRNA Signature for Stratification of Breast Lesions among Women with Abnormal Screening Mammograms

A Circulating miRNA Signature for Stratification of Breast Lesions among Women with Abnormal Screening Mammograms

The circulating miRNAs as diagnostic and prognostic markers

miRNAs in the Diagnosis and Prognosis of Skin Cancer

Contact Info

Product

Resources

About